Άρθρο ανασκόπησης : Ο ρόλος των «ενυδατικών» στην θεραπευτική αντιμετώπιση της ατοπικής δερματίτιδας.

Άρθρο ανασκόπησης : Ο ρόλος των «ενυδατικών» στην θεραπευτική αντιμετώπιση της ατοπικής δερματίτιδας.

 

Sirikudta W, Kulthanan K, Varothai S, Nuchkull P (2013).

Moisturizers for Patients with Atopic Dermatitis: An Overview.

J Allergy Ther 4:143. doi: 10.4172/2155-6121.1000143.

Abstract

Atopic dermatitis is a chronic inflammatory skin condition result from epidermal barrier defect and immune dysfunction. Not only has lesional skin increase pH and transepidermal water loss but also non-lesional skin.

Regular use of moisturizers helps maintain skin hydration and improve barrier dysfunction.

Active ingredients in moisturizers can be classified into :

1) occlusives,

2) humectants, and

3) emollients

 according to their properties.

 Agents with anti-inflammatory effects are also added.

This review mainly focus on active agents in moisturizers claimed of suitable for atopic skin, in order to provide more information and aid physicians in selecting and giving advice to patients with atopic dermatitis.

Η πρόσβαση στο άρθρο είναι ελεύθερη από την ιστοσελίδα του εκδότη:

http://www.omicsonline.org/2155-6121/2155-6121-4-143.php?aid=15728

 

Η κατάλληλη χρήση ενυδατικών παραγόντων ελλατώνει την συχνότητα και την σοβαρότητα των εξάρσεων της ατοπικής δερματίτιδας. Πρόσφατα δεδομένα σχετικά με την κατανόηση της παθοφυσιολογίας της ατοπικής δερματίτιδας και ειδικά την ελλειμματική παραγωγή ενδογενούς φιλαγκρίνης και κεραμιδίων οδήγησαν στην παραγωγή μίας σειράς από φαρμακευτικά ενυδατικά πρόϊόντα τα οποία στοχεύουν στην αναπλήρωση αυτών των ουσιών μέσω τοπικά χορηγούμενων κρεμών και δερματικών αλοιφών :

 

Hon KL, Leung AK, Barankin B.

Barrier Repair Therapy in Atopic Dermatitis: An Overview.

Am J Clin Dermatol. 2013 Jun 12. [Προδημοσίευση]

PubMed PMID: 23757122.

Abstract.

Atopic eczema or dermatitis (AD) is a chronically relapsing dermatitis associated with pruritus, sleep disturbance, psychosocial symptoms, and impaired quality of life. It affects 10-20 % of school-aged children, and there is evidence to suggest that this prevalence is increasing. Filaggrin (filament-aggregating protein) has an important function in epidermal differentiation and barrier function. Null mutations within the filaggrin gene cause ichthyosis vulgaris and appear to be a major risk factor for developing AD. The affected skin of atopic individuals is deficient in filaggrin degradation products or ceramides. Avoidance of triggering factors, optimal skin care, topical corticosteroids, and calcineurin inhibitors are the mainstays of therapy for AD. Proper moisturizer therapy can reduce the frequency and intensity of flares, as well as the need for topical corticosteroids or topical calcineurin inhibitors. Recent advances in the understanding of the pathophysiological process of AD involving filaggrin and ceramides has led to the concept of barrier therapy and the production of new moisturizers and topical skin products targeted to correct reduced amounts of ceramides and natural moisturizing factors in the skin with natural moisturizing factors, ceramides, and pseudoceramide products. Emollients, both creams and ointments, improve the barrier function of the stratum corneum by providing it with water and lipids. Studies on AD and barrier repair treatment show that adequate lipid replacement therapy reduces the inflammation and restores epidermal function. We reviewed 12 randomized trials and 11 cohort studies and found some evidence that certain products had therapeutic efficacy in improving clinical and/or biophysical parameters of patients with AD. Nevertheless, study methods were often flawed and sample sizes were small. Additional research is warranted to better understand the optimal formulary compositions. Also, long-term studies would be important to evaluate whether lipid barrier replacement therapy reduces bacterial colonization or prevents progression of the atopic march.